Platelets in Inflammatory Disorders: A Pathophysiological and Clinical Perspective

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 6, 2015, Pages 572-581

  Thachil, Jecko ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

inflammation; platelets; thrombosis

Indexed keywords

CD40 LIGAND; CHEMOKINE; COMPLEMENT; VON WILLEBRAND FACTOR; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; AUTACOID;

ACUTE LUNG INJURY; ALZHEIMER DISEASE; ASTHMA; CELL INTERACTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DOWN REGULATION; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; LEUKOCYTE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTOPENIA; TRANSFUSION RELATED ACUTE LUNG INJURY; VASCULAR ENDOTHELIUM; AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; BLOOD; CELL COMMUNICATION; COMPLEMENT ACTIVATION; DEFICIENCY; LUNG DISEASE; METABOLISM; NEUROLOGIC DISEASE; PATHOLOGY; PHYSIOLOGY; RHEUMATIC DISEASE; THROMBOSIS;

ADAM PROTEINS; AUTOIMMUNE DISEASES; BLOOD PLATELETS; CELL COMMUNICATION; CHEMOKINES; COMPLEMENT ACTIVATION; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; LUNG DISEASES; MODELS, BIOLOGICAL; NERVOUS SYSTEM DISEASES; PLATELET ADHESIVENESS; RHEUMATIC DISEASES; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 84941810287     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1556589     Document Type: Review

References (88)

1. Opal S. M., Esmon C. T. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care: 2003; 7 1 23 38
2. Delvaeye M., Conway E. M. Coagulation and innate immune responses: can we view them separately? Blood: 2009; 114 12 2367 2374
3. Eming S. A., Krieg T., Davidson J. M. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol: 2007; 127 3 514 525
4. Dahlbäck B. Coagulation and inflammation-close allies in health and disease. Semin Immunopathol: 2012; 34 1 1 3
5. Jin R. C., Voetsch B., Loscalzo J. Endogenous mechanisms of inhibition of platelet function. Microcirculation: 2005; 12 3 247 258
6. Gawaz M., Langer H., May A. E. Platelets in inflammation and atherogenesis. J Clin Invest: 2005; 115 12 3378 3384
7. Gawaz M., Brand K., Dickfeld T., et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis: 2000; 148 1 75 85
8. Antoniades C., Bakogiannis C., Tousoulis D., Antonopoulos A. S., Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol: 2009; 54 8 669 677
9. Pamukcu B., Lip G. Y., Snezhitskiy V., Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann Med: 2011; 43 5 331 340
10. Ho-Tin-Noé B., Demers M., Wagner D. D. How platelets safeguard vascular integrity. J Thromb Haemost: 2011; 9 01 56 65
11. Lip G. Y., Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res: 1997; 34 2 255 265
12. Pottinger B. E., Read R. C., Paleolog E. M., Higgins P. G., Pearson J. D. von Willebrand factor is an acute phase reactant in man. Thromb Res: 1989; 53 4 387 394
13. Thachil J. The difficult distinction between antiphospholipid syndrome and thrombotic thrombocytopenic purpura. Br J Haematol: 2010; 149 2 294 295
14. Thachil J. Lessons from acute pancreatitis-induced thrombotic thrombocytopenic purpura. Eur J Intern Med: 2009; 20 8 739 743
15. van Mourik J. A., Boertjes R., Huisveld I. A., et al. von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood: 1999; 94 1 179 185
16. Chauhan A. K., Kisucka J., Brill A., Walsh M. T., Scheiflinger F., Wagner D. D. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med: 2008; 205 9 2065 2074
17. Yang J., Furie B. C., Furie B. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost: 1999; 81 1 1 7
18. Zarbock A., Polanowska-Grabowska R. K., Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev: 2007; 21 2 99 111
19. van Gils J. M., Zwaginga J. J., Hordijk P. L. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol: 2009; 85 2 195 204
20. Ghasemzadeh M., Hosseini E. Platelet-leukocyte crosstalk: Linking proinflammatory responses to procoagulant state. Thromb Res: 2013; 131 3 191 197
21. von Hundelshausen P., Petersen F., Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost: 2007; 97 5 704 713
22. Li N. Platelet-lymphocyte cross-talk. J Leukoc Biol: 2008; 83 5 1069 1078
23. Corken A., Russell S., Dent J., Post S. R., Ware J. Platelet glycoprotein Ib-IX as a regulator of systemic inflammation. Arterioscler Thromb Vasc Biol: 2014; 34 5 996 1001
24. Polley M. J., Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med: 1978; 147 6 1713 1726
25. Peerschke E. I., Yin W., Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol: 2010; 47 13 2170 2175
26. Del Conde I., Crúz M. A., Zhang H., López J. A., Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med: 2005; 201 6 871 879
27. Hamad O. A., Bäck J., Nilsson P. H., Nilsson B., Ekdahl K. N. Platelets, complement, and contact activation: partners in inflammation and thrombosis. Adv Exp Med Biol: 2012; 946 185 205
28. Karshovska E., Weber C., von Hundelshausen P. Platelet chemokines in health and disease. Thromb Haemost: 2013; 110 5 894 902
29. Kaplan Z. S., Jackson S. P. The role of platelets in atherothrombosis. Hematology (Am Soc Hematol Educ Program): 2011; 2011 11 51 61
30. Smid J., Braun-Dullaeus R., Gawaz M., Langer H. F. Platelet interactions as therapeutic targets for prevention of atherothrombosis. Future Cardiol: 2009; 5 3 285 296
31. Zucker-Franklin D., Philipp C. S. Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept. Am J Pathol: 2000; 157 1 69 74
32. Trowbridge E. A., Martin J. F., Slater D. N. Evidence for a theory of physical fragmentation of megakaryocytes, implying that all platelets are produced in the pulmonary circulation. Thromb Res: 1982; 28 4 461 475
33. Dickinson C. J., Martin J. F. Megakaryocytes and platelet clumps as the cause of finger clubbing. Lancet: 1987; 2 8573 1434 1435
34. Bozza F. A., Shah A. M., Weyrich A. S., Zimmerman G. A. Amicus or adversary: platelets in lung biology, acute injury, and inflammation. Am J Respir Cell Mol Biol: 2009; 40 2 123 134
35. Schneider R. C., Zapol W. M., Carvalho A. C. Platelet consumption and sequestration in severe acute respiratory failure. Am Rev Respir Dis: 1980; 122 3 445 451
36. Bone R. C., Francis P. B., Pierce A. K. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med: 1976; 61 5 585 589
37. Peng X., Hassoun P. M., Sammani S., et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med: 2004; 169 11 1245 1251
38. Zarbock A., Singbartl K., Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest: 2006; 116 12 3211 3219
39. O'Sullivan B. P., Michelson A. D. The inflammatory role of platelets in cystic fibrosis. Am J Respir Crit Care Med: 2006; 173 5 483 490
40. Gross S., Luckey C. The oxygen tension-platelet relationship in cystic fibrosis. Am Rev Respir Dis: 1969; 100 4 513 517
41. O'Sullivan B. P., Linden M. D., Frelinger A. L. III., et al. Platelet activation in cystic fibrosis. Blood: 2005; 105 12 4635 4641
42. Abraham E. H., Sterling K. M., Kim R. J., et al. Erythrocyte membrane ATP binding cassette (ABC) proteins: MRP1 and CFTR as well as CD39 (ecto-apyrase) involved in RBC ATP transport and elevated blood plasma ATP of cystic fibrosis. Blood Cells Mol Dis: 2001; 27 1 165 180
43. Ciabattoni G., Davì G., Collura M., et al. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am J Respir Crit Care Med: 2000; 162 (4, Pt 1): 1195 1201
44. Page C., Pitchford S. Platelets and allergic inflammation. Clin Exp Allergy: 2014; 44 7 901 913
45. Dürk T., Duerschmied D., Müller T., et al. Production of serotonin by tryptophan hydroxylase 1 and release via platelets contribute to allergic airway inflammation. Am J Respir Crit Care Med: 2013; 187 5 476 485
46. Yoshida A., Ohba M., Wu X., Sasano T., Nakamura M., Endo Y. Accumulation of platelets in the lung and liver and their degranulation following antigen-challenge in sensitized mice. Br J Pharmacol: 2002; 137 2 146 152
47. Svensson Holm A. C., Bengtsson T., Grenegård M., Lindström E. G. Platelet membranes induce airway smooth muscle cell proliferation. Platelets: 2011; 22 1 45 55
48. Vlaar A. P., Juffermans N. P. Transfusion-related acute lung injury: a clinical review. Lancet: 2013; 382 9896 984 994
49. Caudrillier A., Kessenbrock K., Gilliss B. M., et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest: 2012; 122 7 2661 2671
50. Looney M. R., Nguyen J. X., Hu Y., Van Ziffle J. A., Lowell C. A., Matthay M. A. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest: 2009; 119 11 3450 3461
51. Serebruany V. L. Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel. Thromb Haemost: 2012; 108 6 1024 1027
52. Maclay J. D., McAllister D. A., Johnston S., et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax: 2011; 66 9 769 774
53. Harrison M. T., Short P., Williamson P. A., Singanayagam A., Chalmers J. D., Schembri S. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for anti-platelet therapy? Thorax Published Online First: 2014; 69 7 609 615
54. Gasparyan A. Y., Stavropoulos-Kalinoglou A., Mikhailidis D. P., Douglas K. M., Kitas G. D. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int: 2011; 31 2 153 164
55. Pamuk G. E., Vural O., Turgut B., Demir M., Pamuk O. N., Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets: 2008; 19 2 146 154
56. Knijff-Dutmer E. A., Koerts J., Nieuwland R., Kalsbeek-Batenburg E. M., van de Laar M. A. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum: 2002; 46 6 1498 1503
57. Ertenli I., Kiraz S., Arici M., et al. P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. J Rheumatol: 1998; 25 6 1054 1058
58. Mac Mullan P. A., Peace A. J., Madigan A. M., Tedesco A. F., Kenny D., McCarthy G. M. Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: a novel finding and potential therapeutic target. Rheumatology (Oxford): 2010; 49 2 240 245
59. Boilard E., Nigrovic P. A., Larabee K., et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science: 2010; 327 5965 580 583
60. Cloutier N., Paré A., Farndale R. W., et al. Platelets can enhance vascular permeability. Blood: 2012; 120 6 1334 1343
61. Postlethwaite A. E., Chiang T. M. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol: 2007; 19 6 574 579
62. Dees C., Akhmetshina A., Zerr P., et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med: 2011; 208 5 961 972
63. Pauling J. D., O'Donnell V. B., Mchugh N. J. The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis. Platelets: 2013; 24 7 503 515
64. Maugeri N., Franchini S., Campana L., et al. Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity: 2012; 45 8 584 587
65. Ziakas P. D., Giannouli S., Zintzaras E., Tzioufas A. G., Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis: 2005; 64 9 1366 1369
66. Zhao H., Li S., Yang R. Thrombocytopenia in patients with systemic lupus erythematosus: significant in the clinical implication and prognosis. Platelets: 2010; 21 5 380 385
67. Garcia-Romo G. S., Caielli S., Vega B., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med: 2011; 3 73 73ra20
68. Clark S. R., Ma A. C., Tavener S. A., et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med: 2007; 13 4 463 469
69. Fuchs T. A., Brill A., Duerschmied D., et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A: 2010; 107 36 15880 15885
70. Lood C., Eriksson S., Gullstrand B., et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus-a possible link to venous thrombosis? Lupus: 2012; 21 13 1423 1432
71. Delmas Y., Viallard J. F., Solanilla A., et al. Activation of mesangial cells by platelets in systemic lupus erythematosus via a CD154-dependent induction of CD40. Kidney Int: 2005; 68 5 2068 2078
72. Tanaka T., Kuroiwa T., Ikeuchi H., et al. Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40/CD40 ligand pathway and may amplify glomerular injury. J Am Soc Nephrol: 2002; 13 10 2488 2496
73. Voudoukis E., Karmiris K., Koutroubakis I. E. Multipotent role of platelets in inflammatory bowel diseases: a clinical approach. World J Gastroenterol: 2014; 20 12 3180 3190
74. Morowitz D. A., Allen L. W., Kirsner J. B. Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med: 1968; 68 5 1013 1021
75. Thachil J. Extreme thrombocytosis-an unusual presentation of inflammatory bowel disease. Intern Med: 2008; 47 13 1255 1257
76. Kulnigg-Dabsch S., Evstatiev R., Dejaco C., Gasche C. Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS ONE: 2012; 7 4 e34520
77. Kulnigg-Dabsch S., Schmid W., Howaldt S., et al. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis: 2013; 19 8 1609 1616
78. Danese S., de la Motte C., Sturm A., et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology: 2003; 124 5 1249 1264
79. Danese S., Scaldaferri F., Vetrano S., et al. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut: 2007; 56 9 1248 1256
80. Irving P. M., Macey M. G., Shah U., Webb L., Langmead L., Rampton D. S. Formation of platelet-leukocyte aggregates in inflammatory bowel disease. Inflamm Bowel Dis: 2004; 10 4 361 372
81. Andoh A., Tsujikawa T., Hata K., et al. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol: 2005; 100 9 2042 2048
82. Sheremata W. A., Jy W., Horstman L. L., Ahn Y. S., Alexander J. S., Minagar A. Evidence of platelet activation in multiple sclerosis. J Neuroinflammation: 2008; 5 27
83. Thornton P., McColl B. W., Greenhalgh A., Denes A., Allan S. M., Rothwell N. J. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood: 2010; 115 17 3632 3639
84. Bush A. I., Martins R. N., Rumble B., et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem: 1990; 265 26 15977 15983
85. Zhang W., Huang W., Jing F. Contribution of blood platelets to vascular pathology in Alzheimer's disease. J Blood Med: 2013; 4 141 147
86. Ciabattoni G., Porreca E., Di Febbo C., et al. Determinants of platelet activation in Alzheimer's disease. Neurobiol Aging: 2007; 28 3 336 342
87. Prodan C. I., Ross E. D., Vincent A. S., Dale G. L. Coated-platelets correlate with disease progression in Alzheimer disease. J Neurol: 2007; 254 4 548 549
88. Bentham P., Gray R., Sellwood E., Hills R., Crome P., Raftery J.; AD2000 Collaborative Group. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol: 2008; 7 1 41 49